- Previous Close
645.45 - Open
641.10 - Bid --
- Ask --
- Day's Range
641.10 - 668.80 - 52 Week Range
559.95 - 862.60 - Volume
16,588 - Avg. Volume
26,307 - Market Cap (intraday)
19.243B - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
39.08 - EPS (TTM)
17.04 - Earnings Date May 21, 2025 - May 26, 2025
- Forward Dividend & Yield 5.60 (0.87%)
- Ex-Dividend Date Feb 18, 2025
- 1y Target Est
--
Amrutanjan Health Care Limited manufactures, supplies, and sells ayurvedic pain balms and women hygiene products. The company operates through OTC Products, Beverages, and Others segments. It provides pain management products comprising pain balms and roll-ons; and back pain roll-ons, stick-on patch, body pain gels, and joint muscle sprays. The company offers congestion management products that consists of cold rubs, cough syrups, nasal inhalers, and swas mints. It also provides sanitary napkins for women. In addition, the company offers corn caps; dental gel; hand sanitizers; and juice drinks under the Fruitnik and Fruitnik Electro+ brand names, as well as operates a pain management center. It exports its products to the Middle East, Africa, the Southeast Asia, and internationally. The company was formerly known as Amrutanjan Limited and changed its name to Amrutanjan Health Care Limited in 2007. Amrutanjan Health Care Limited was founded in 1893 and is based in Chennai, India.
www.amrutanjan.com634
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: AMRUTANJAN.NS
View MorePerformance Overview: AMRUTANJAN.NS
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMRUTANJAN.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMRUTANJAN.NS
View MoreValuation Measures
Market Cap
18.64B
Enterprise Value
16.37B
Trailing P/E
37.88
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.22
Price/Book (mrq)
6.26
Enterprise Value/Revenue
3.70
Enterprise Value/EBITDA
21.96
Financial Highlights
Profitability and Income Statement
Profit Margin
11.12%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
4.44B
Net Income Avi to Common (ttm)
493.16M
Diluted EPS (ttm)
17.04
Balance Sheet and Cash Flow
Total Cash (mrq)
2.29B
Total Debt/Equity (mrq)
0.74%
Levered Free Cash Flow (ttm)
--